LQDA vs MNKD
LQDA: Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering, for pulmonary hypertension. MNKD: MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic and orphan lung diseases.
Side-by-side fundamentals
| Metric | LQDA | MNKD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $87.04 | $3.84 | |
| Market cap as of 2026-07-23 | $7.7B | $1.2B | |
| P/E as of 2026-07-23 | 347.02 | 212.36 | MNKD lower |
| Net margin as of 2026-07-23 | +7.7% | -6.4% | LQDA higher |
| Gross margin as of 2026-07-23 | +91.8% | +78.4% | LQDA higher |
| Operating margin as of 2026-07-23 | +15.8% | +4.1% | LQDA higher |
| ROE as of 2026-07-23 | +46.8% | -297.7% | LQDA higher |
| ROA as of 2026-07-23 | +7.1% | -3.8% | LQDA higher |
| Debt / equity as of 2026-07-23 | 1.64 | 9.95 | LQDA lower |
| Revenue growth (YoY) as of 2026-07-23 | +1936.7% | +21.2% | LQDA higher |
| Revenue CAGR (3y) SEC XBRL | +115.0% | +51.8% | LQDA higher |
| Beta as of 2026-07-23 | 0.58 | 1.12 | |
| 1-year return as of 2026-07-22 close | +424.3% | -2.3% | LQDA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.